EMA Application withdrawn: Zynyz (retifanlimab) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

The EMA has withdrawn the application for Zynyz (retifanlimab) by Incyte Biosciences Distribution B.V. for anus neoplasms and squamous cell carcinoma indication…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anus Neoplasms
• Carcinoma Squamous Cell

Drugs mentioned

• ZYNYZ (RETIFANLIMAB-DLWR)

Snippet

Status: Application withdrawn. Therapeutic area: Anus Neoplasms;Carcinoma, Squamous Cell. MAH: Incyte Biosciences Distribution B.V.